Stress-mediated polysorbate 20 degradation and its potential impact on therapeutic proteins
Authors:
Open Access
- 13 May 2024
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 41 (6) , 1217-1232
Abstract
Purpose: Polysorbates are the most commonly used surfactants in formulations to stabilize therapeutic proteins against interfacial stresses. Polysorbates can undergo oxidative or enzyme-mediated hydrolytic degradation to produce free fatty acids (FFAs) and subvisible particles in formulations. To determine which product related variables contribute to PS20 degradation, we investigated the effects of storage temperature, formulation, pH, presence of hydrolytic enzymes, and specific fatty acid composition on different grades of PS20 in relation to their PS20 degradation profile and consequently the quality of protein drug products. Methods: Bevacizumab and T-DM1 were reformulated in the freshly prepared therapeutic protein formulations containing either compendial PS20 or non-compendial PS20 with high % lauric acid and spiked with exogenous esterase or lipase. The release of FFAs and formation of particles were monitored at 4°C and 37°C. Protein quality was assessed for secondary structures, purity, and biological activity. Results: Hydrolytic release of FFAs and formation of subvisible particles were found to be dependent on grades of PS20, types of enzymes used, incubation temperature, and pH. Esterase- or lipase-mediated degradation of PS20 and formation of subvisible particles in drug formulation showed no significant impact on the biological activity and stability of therapeutic proteins against degradation or aggregation. Conclusions: Our study suggests that degradation of PS20 and formation of FFA particles depend on the fatty acid composition of PS20, types of hydrolytic enzymes, pH, and temperature. The presence of FFA subvisible particles showed no significant impact on the purity and biological activity of the therapeutic proteins under the tested conditions.Keywords
This publication has 43 references indexed in Scilit:
- A Comprehensive Scientific Survey of Excipients Used in Currently Marketed, Therapeutic Biological Drug ProductsPharmaceutical Research, 2020
- Knockout of a difficult‐to‐remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulationsBiotechnology and Bioengineering, 2016
- Identification of Subvisible Particles in Biopharmaceutical Formulations Using Raman Spectroscopy Provides Insight into Polysorbate 20 Degradation PathwayPharmaceutical Research, 2015
- Free Fatty Acid Particles in Protein Formulations, Part 2: Contribution of Polysorbate Raw MaterialJournal of Pharmaceutical Sciences, 2015
- Free Fatty Acid Particles in Protein Formulations, Part 1: Microspectroscopic IdentificationJournal of Pharmaceutical Sciences, 2015
- Ester Hydrolysis of Polysorbate 80 in mAb Drug Product: Evidence in Support of the Hypothesized Risk After the Observation of Visible Particulate in mAb FormulationsJournal of Pharmaceutical Sciences, 2014
- Compatibility, Physical Stability, and Characterization of an IgG4 Monoclonal Antibody After Dilution into Different Intravenous Administration BagsJournal of Pharmaceutical Sciences, 2012
- The Degradation of Polysorbates 20 and 80 and its Potential Impact on the Stability of BiotherapeuticsPharmaceutical Research, 2011
- Polysorbates 20 and 80 Used in the Formulation of Protein Biotherapeutics: Structure and Degradation PathwaysJournal of Pharmaceutical Sciences, 2008
- Autoxidation of PolysorbatesJournal of Pharmaceutical Sciences, 1978